The emerging functions and clinical implications of circRNAs in acute myeloid leukaemia

Table 6 Correlation between circRNAs and clinicopathological characteristics of AML

Clinicopathologic features	Significantly associated circRNAs (P < 0.05)	References
Age	Circ_0001187	[156]
Sex: female	CircSMC1 A	[172]
FAB subtype	CircEHBP1	[167]
Percentages of blasts in BM	Circ_001264 Hsa_circ_0001947 Circ_0001187 Circ-ANAPC7 Circ-PVT1	[150] [152] [156] [173] [174]
Percentages of blasts in PB	Hsa_circ_0001947 Circ_0001187 CircKLHL8	[152] [156] [172]
WBC count	Hsa_circ_0001947 Circ_0001187 CircFCHO2 Circ-ANAPC7 Hsa_circ_0079480	[152] [156] [172] [173] [175]
PLT count	Circ_0001187	[156]
HGB level	CircTASP1 Hsa_circ_0001947 Circ_0001187	[75] [152] [156]
NPM1 mutation	CircFCHO2	[172]
FLT3-ITD	CircKLHL8 CircSMC1 A CircCFLAR CircFCHO2 Circ-PVT1	[172] [172] [172] [172] [174]
WT1 mutation	CircCFLAR	[172]
CEBPA Double mutation	CircFCHO2	[172]

circRNA circular RNA, AML acute myeloid leukaemia, FAB French-American-British, BM bone marrow, PB peripheral blood, WBC white blood cell, PLT platelet, HGB haemoglobin, NPM1 nucleophosmin, FLT3 FMS-like tyrosine kinase-3, ITD internal tandem duplication, CEBPA CCAAT Enhancer Binding Protein A, WT1 Wilms’ Tumor 1

ISSN: 1475-2867